MicroRNA-126-3p as a predictive biomarker for patients with primary biliary cholangitis refractory to ursodeoxycholic acid

Figure 2 Primary biliary cholangitis patients with high baseline miR-126-3p expression are sensitive to ursodeoxycholic acid, miR-126-3p expression was consistently upregulated after receiving ursodeoxycholic acid treatment and correlated with liver function. A: Differentially expressed microRNAs (miRNAs) screened by sequencing were validated by quantitative real-time polymerase chain reaction in the discovery cohort; B: The top three differentially expressed folds of miRNAs from sequencing were selected in the test cohort for quantitative real-time polymerase chain reaction validation; C: Receiver operating characteristic curve analysis of miR-126-3p expression as a predictor of ursodeoxycholic acid efficacy; D: Comparison of miR-126-3p expression before and after treatment in primary biliary cholangitis patients in the test cohort; E: Correlation between miR-126-3p expression and liver function indexes. ^aP < 0.05; ^bP < 0.01; ^cP < 0.005; ^dP < 0.001. DRpre: Drug resistance pre-treatment; DRpost: Drug resistance post-treatment; DSpre: Drug sensitive pre-treatment; DSpost: Drug sensitive post-treatment; AUC: Area under the curve; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; GGT: Gamma-glutamyl transferase; TBIL: Total bilirubin; IgG: Immunoglobulin G.